REFERENCES
Alshamy Z, Richardson KC, Hünigen H, Hafez HM, Plendl J, & Al Masri S (2018). Comparison of the gastrointestinal tract of a dual-purpose to a broiler chicken line: A qualitative and quantitative macroscopic and microscopic study. PLoS ONE.
Anderson CMH, & Thwaites DT (2005). Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). Journal of Cellular Physiology.
Barone S, Fussell SL, Singh AK, Lucas F, Xu J, Kim C, et al.(2009). Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. Journal of Biological Chemistry.
Beaufils F, Mas E, Mittaine M, Addra M, Fayon M, Delhaes L, et al. (2020). Increased fecal calprotectin is associated with worse gastrointestinal symptoms and quality of life scores in children with cystic fibrosis. Journal of Clinical Medicine.
Bleich A, & Tolba RH (2017). How can we assess their suffering? German research consortium aims at defining a severity assessment framework for laboratory animals.
Block GA, Bleyer AJ, Silva AL, Weiner DE, Lynn RI, Yang Y, et al.(2021). Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360.
Borowitz D, & Gelfond D (2013). Intestinal complications of cystic fibrosis.
Bradford EM, Sartor MA, Gawenis LR, Clarke LL, & Shull GE (2009). Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, et al. (2004). Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Alimentary Pharmacology and Therapeutics.
Carroll W, Green J, & Gilchrist FJ (2021). Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Clarke LL, Gawenis LR, Franklin CL, & Harline MC (1996). Increased Survival of CFTR Knockout Mice with an Oral Osmotic Laxative. Laboratory Animal Science.
Crites KSM, Morin G, Orlando V, Patey N, Cantin C, Martel J, et al. (2015). CFTR Knockdown induces proinflammatory changes in intestinal epithelial cells. Journal of Inflammation (United Kingdom).
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers.
De Lisle RC (2007). Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Dellschaft NS, Ng C, Hoad C, Marciani L, Spiller R, Stewart I, et al. (2021). Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls. Journal of Cystic Fibrosis.
Dorsey J, & Gonska T (2017). Bacterial overgrowth, dysbiosis, inflammation, and dysmotility in the Cystic Fibrosis intestine. Journal of Cystic Fibrosis.
Faul F, Erdfelder E, Lang AG, & Buchner A G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences.
Foulke-Abel J, In J, Yin J, Zachos NC, Kovbasnjuk O, Estes MK, et al. (2016). Human Enteroids as a Model of Upper Small Intestinal Ion Transport Physiology and Pathophysiology. Gastroenterology.
Gallagher AM, & Gottlieb RA (2001). Proliferation, not apoptosis, alters epithelial cell migration in small intestine of CFTR null mice. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Galli F, Battistoni A, Gambari R, Pompella A, Bragonzi A, Pilolli F, et al. (2012). Oxidative stress and antioxidant therapy in cystic fibrosis.
Gilchrist FJ, Green J, & Carroll W (2021). Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis.
Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, et al. (2022). Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. American Journal of Respiratory and Critical Care Medicine.
Hayee BH, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, et al. (2019). A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterology Journal.
Hite M, Gaertner WB, Garcia B, Flume P, Maxwell JP, George VV, et al. (2022). Abdominal Surgical Procedures in Adult Patients with Cystic Fibrosis. Diseases of the Colon & Rectum.
Honda S, Loher P, Morichika K, Shigematsu M, Kawamura T, Kirino Y, et al. (2017). Increasing cell density globally enhances the biogenesis of Piwi-interacting RNAs in Bombyx mori germ cells. Scientific Reports.
Houwen RH, Van Der Doef HP, Sermet I, Munck A, Hauser B, Walkowiak J, et al. (2010). Defining DIOS and constipation in cystic fibrosis with a multicentre study on the incidence, characteristics, and treatment of DIOS. Journal of Pediatric Gastroenterology and Nutrition.
Jakab RL, Collaco AM, & Ameen NA (2011). Physiological relevance of cell-specific distribution patterns of CFTR, NKCC1, NBCe1, and NHE3 along the crypt-villus axis in the intestine. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Jaudszus A, Pfeifer E, Lorenz M, Beiersdorf N, Hipler UC, Zagoya C, et al. (2022). Abdominal Symptoms Assessed with the CFAbd-Score are Associated with Intestinal Inflammation in Patients with Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition.
Johansson S, Rosenbaum DP, Palm J, Stefansson B, Knutsson M, Lisbon EA, et al. (2017). Tenapanor administration and the activity of the H+-coupled transporter PepT1 in healthy volunteers. British Journal of Clinical Pharmacology.
Kini A, Singh AK, Riederer B, Yang I, Tan Q, di Stefano G, et al.(2020). Slc26a3 deletion alters pH-microclimate, mucin biosynthesis, microbiome composition and increases the TNFα expression in murine colon. Acta Physiologica.
Kini A, Zhao B, Basic M, Roy U, Iljazovic A, Odak I, et al.(2022). Upregulation of antimicrobial peptide expression in slc26a3-/- mice with colonic dysbiosis and barrier defect. Gut Microbes.
Lavie M, Manovitz T, Vilozni D, Levy-Mendelovich S, Sarouk I, Weintraubv I, et al. (2015). Long-term follow-up of distal intestinal obstruction syndrome in cystic fibrosis. World Journal of Gastroenterology.
Lisowska A, Mdry E, Pogorzelski A, Szydłowski J, Radzikowski A, & Walkowiak J (2010). Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scandinavian Journal of Clinical and Laboratory Investigation.
Liu J, Walker NM, Cook MT, Ootani A, & Clarke LL (2012). Functional Cftr in crypt epithelium of organotypic enteroid cultures from murine small intestine. American Journal of Physiology - Cell Physiology.
Lord R, Fairbourn N, Mylavarapu C, Dbeis A, Bowman T, Chandrashekar A, et al. (2018). Consuming genistein improves survival rates in the absence of laxative in ∆F508-CF female mice. Nutrients.
Malagelada C, Bendezú RA, Seguí S, Vitrià J, Merino X, Nieto A, et al. (2020). Motor dysfunction of the gut in cystic fibrosis. Neurogastroenterology and Motility.
Malmberg EK, Noaksson KA, Phillipson M, Johansson MEV, Hinojosa-Kurtzberg M, Holm L, et al. (2006). Increased levels of mucins in the cystic fibrosis mouse small intestine, and modulator effects of the Muc1 mucin expression. American Journal of Physiology-Gastrointestinal and Liver Physiology 291:G203-G210.
Munck A, Alberti C, Colombo C, Kashirskaya N, Ellemunter H, Fotoulaki M, et al. (2016). International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome. Journal of Cystic Fibrosis.
Norkina O, Kaur S, Ziemer D, & De Lisle RC (2004). Inflammation of the cystic fibrosis mouse small intestine. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Ooi CY, Syed SA, Rossi L, Garg M, Needham B, Avolio J, et al.(2018). Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Scientific Reports.
Parmley RR, & Gendler SJ (1998). Cystic fibrosis mice lacking Muc1 have reduced amounts of intestinal mucus. Journal of Clinical Investigation.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. British Journal of Pharmacology.
Philp AR, Riquelme TT, Millar-Büchner P, González R, Sepúlveda FV, Cid LP, et al. (2018). Kcnn4 is a modifier gene of intestinal cystic fibrosis preventing lethality in the CFTR-F508del mouse. Scientific Reports.
Raia V, Maiuri L, De Ritis G, De Vizia B, Vacca L, Conte R, et al. (2000). Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatric Research.
Ratcliff R, Evans MJ, Cuthbert AW, MacVinish LJ, Foster D, Anderson JR, et al. (1993). Production of a severe cystic fibrosis mutation in mice by gene targeting. Nature Genetics 4: 35-41.
Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, Taft PJ, et al. (2008). Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science.
Sharma A, Morton A, Peckham D, & Jayne D (2012). Gastrointestinal surgery in adult patients with cystic fibrosis. Frontline Gastroenterology.
Shawki A, Engevik MA, Kim RS, Knight PB, Baik RA, Anthony SR, et al. (2016). Intestinal brush-border Na+/H+ exchanger-3 drives H+-coupled iron absorption in the mouse. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Simpson JE, Gawenis LR, Walker NM, Boyle KT, & Clarke LL (2005). Chloride conductance of CFTR facilitates basal Cl -/HCO 3- exchange in the villous epithelium of intact murine duodenum. American Journal of Physiology - Gastrointestinal and Liver Physiology.
Sinagra E, Rossi F, Raimondo D, Conoscenti G, Anderloni A, Guarnotta V, et al. (2020). Tenapanor for the treatment of irritable bowel syndrome with constipation. Expert Review of Clinical Pharmacology.
Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, et al. (1992). An animal model for cystic fibrosis made by gene targeting. Science.
Stoltz DA, Rokhlina T, Ernst SE, Pezzulo AA, Ostedgaard LS, Karp PH, et al. (2013). Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. Journal of Clinical Investigation.
Strubberg AM, Liu J, Walker NM, Stefanski CD, MacLeod RJ, Magness ST, et al. (2018). Cftr Modulates Wnt/β-Catenin Signaling and Stem Cell Proliferation in Murine Intestine. Cellular and Molecular Gastroenterology and Hepatology 5: 253-271.
Talebi S, Day AS, Rezaiyan MK, Ranjbar G, Zarei M, Safarian M, et al. (2022). Fecal Calprotectin and Phenotype Severity in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis. Pediatric Gastroenterology, Hepatology and Nutrition.
Tan Q, di Stefano G, Tan X, Renjie X, Römermann D, Talbot SR, et al. (2021). Inhibition of Na+/H+ exchanger isoform 3 improves gut fluidity and alkalinity in cystic fibrosis transmembrane conductance regulator-deficient and F508del mutant mice. British Journal of Pharmacology.
Tétard C, Mittaine M, Bui S, Beaufils F, Maumus P, Fayon M, et al. (2020). Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis. Journal of pediatric gastroenterology and nutrition.
Thwaites DT, & Anderson CMH (2007). H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine.
Vitko M, Valerio DM, Rye PD, Onsøyen E, Myrset AH, Dessen A, et al. (2016). A novel guluronate oligomer improves intestinal transit and survival in cystic fibrosis mice. Journal of Cystic Fibrosis.
Walker NM, Simpson JE, Levitt RC, Boyle KT, & Clarke LL (2006). Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome. Journal of Pharmacology and Experimental Therapeutics.
Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, et al. (2010). Evidence of intestinal inflammation in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition.
Xiao F, Li J, Singh AK, Riederer B, Wang J, Sultan A, et al.(2012). Rescue of epithelial HCO 3 − secretion in murine intestine by apical membrane expression of the cystic fibrosis transmembrane conductance regulator mutant F508del. The Journal of Physiology 590: 5317-5334.